Related Experiment Videos
A new angiogenesis inhibitor, FR-111142
T Otsuka1, T Shibata, Y Tsurumi
1Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan.
The Journal of Antibiotics
|March 1, 1992
Summary
FR-111142, a novel angiogenesis inhibitor from Scolecobasidium arenarium, effectively blocks new blood vessel formation. This compound also demonstrates significant potential in suppressing solid tumor growth in preclinical models.
Area of Science:
- Biochemistry
- Pharmacology
- Mycology
Background:
- Angiogenesis is crucial for tumor growth and metastasis.
- Developing effective angiogenesis inhibitors is a key strategy in cancer therapy.
- Natural products offer a promising source for novel therapeutic agents.
Purpose of the Study:
- To investigate the anti-angiogenic properties of FR-111142, a novel compound isolated from Scolecobasidium arenarium.
- To evaluate the efficacy of FR-111142 in inhibiting endothelial cell proliferation and tumor growth.
Main Methods:
- In vitro assessment of endothelial cell proliferation.
- In vivo evaluation using the chick chorioallantoic membrane (CAM) assay for angiogenesis.
- Preclinical testing of tumor growth suppression in mouse models.
Main Results:
- FR-111142 significantly inhibited endothelial cell proliferation in vitro.
- The compound demonstrated potent anti-angiogenic activity in the chick CAM model.
- FR-111142 effectively suppressed solid tumor growth in mice.
Conclusions:
- FR-111142 is a potent angiogenesis inhibitor with therapeutic potential.
- This fungal-derived compound warrants further investigation for cancer treatment applications.
- Natural product discovery continues to yield promising anti-cancer drug candidates.